Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials

BMC Psychiatry

John Panagides¹  Mary Mackle²  Kari R Nations²  Arjen van Willigenburg³  Jun Zhao²  Armin Szegedi² 

[1] At Time of Research: Schering-Plough (formerly Organon), now Merck Research Laboratories, Summit, NJ, USA;Merck Research Laboratories, Rahway, NJ, USA;At Time of Research: Schering-Plough (formerly Organon), Roseland, NJ, USA

关键词: post hoc analysis;    depressive symptoms;    bipolar I disorder;    asenapine;   

Others  :  1124535
DOI  :  10.1186/1471-244X-11-101

 received in 2010-12-21, accepted in 2011-06-20,  发布年份 2011

【 摘 要 】

Background

Asenapine demonstrated superiority over placebo for mania in bipolar I disorder patients experiencing acute current manic or mixed episodes in 2 randomized, placebo-and olanzapine-controlled trials. We report the results of exploratory pooled post hoc analyses from these trials evaluating asenapine's effects on depressive symptoms in patients from these trials with significant baseline depressive symptoms.

Methods

In the original trials (A7501004 [NCT00159744], A7501005 [NCT00159796]), 977 patients were randomized to flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter), placebo, or oral olanzapine 5-20 mg once daily for 3 weeks. Three populations were defined using baseline depressive symptoms: (1) Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥20 (n = 132); (2) Clinical Global Impression for Bipolar Disorder-Depression (CGI-BP-D) scale severity score ≥4 (n = 170); (3) diagnosis of mixed episodes (n = 302) by investigative site screening. For each population, asenapine and olanzapine were independently compared with placebo using least squares mean change from baseline on depressive symptom measures.

Results

Decreases in MADRS total score were statistically greater with asenapine versus placebo at days 7 and 21 in all populations; differences between olanzapine and placebo were not significant. Decreases in CGI-BP-D score were significantly greater with asenapine versus placebo at day 7 in all categories and day 21 in population 1; CGI-BP-D score reductions were significantly greater with olanzapine versus placebo at day 21 in population 1 and day 7 in populations 2 and 3.

Conclusions

These post hoc analyses show that asenapine reduced depressive symptoms in bipolar I disorder patients experiencing acute manic or mixed episodes with clinically relevant depressive symptoms at baseline; olanzapine results appeared to be less consistent. Controlled studies of asenapine in patients with acute bipolar depression are necessary to confirm the generalizability of these findings.

【 授权许可】

   
2011 Szegedi et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Diagnostic and Statistical Manual of Mental Disorders. Text Revision. Fourth edition. Arlington, VA: American Psychiatric Association; 2000.
• [2]McIntyre RS, Muzina DJ, Kemp DE, Blank D, Woldeyohannes HO, Lofchy J, Soczynska JK, Banik S, Konarski JZ: Bipolar disorder and suicide: research synthesis and clinical translation. Curr Psychiatry Rep 2008, 10(1):66-72.
• [3]Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002, 59(6):530-537.
• [4]Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unutzer J: Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry 2007, 68(8):1237-1245.
• [5]Tondo L, Isacsson G, Baldessarini R: Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003, 17(7):491-511.
• [6]Baldessarini RJ, Vieta E, Calabrese JR, Tohen M, Bowden CL: Bipolar depression: overview and commentary. Harv Rev Psychiatry 2010, 18(3):143-157.
• [7]The World Health Report 2001 - Mental Health: New Understanding, New Hope [http://www.who.int/whr/2001/en/whr01_en.pdf] webcite
• [8]Seroquel® (quetiapine fumarate) Wilmington, DE: AstraZeneca; 2009.
• [9]Symbyax® (olanzapine and fluoxetine hydrochloride) Indianapolis, IN: Eli Lilly and Company; 2010.
• [10]Shahid M, Walker GB, Zorn SH, Wong EH: Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009, 23(1):65-73.
• [11]Saphris® (asenapine sublingual tablets) Whitehouse Station, NJ: Schering Corporation, a subsidiary of Merck & Co., Inc; 2010.
• [12]European Medicines Agency. Sycrest® (asenapine) [http:/ / www.ema.europa.eu/ ema/ index.jsp?curl=pages/ medicines/ human/ medicines/ 001177/ human_med_001379.jsp&murl=menus/ medicines/ medicines.jsp&mid=WC0b01ac058001d12 4&jsenabled=true] webcite
• [13]Marston HM, Martin FDC, Papp M, Gold LH, Wong EHF, Shahid M: Attenuation of chronic mild stress-induced "anhedonia" by asenapine is not associated with a "hedonic" profile in intracranial self-stimulation. J Psychopharmacol (Oxf) 2010, in press.
• [14]McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009, 11(7):673-686.
• [15]McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010, 122(1-2):27-38.
• [16]McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J: Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 2009, 11(8):815-826.
• [17]McIntyre RS, Cohen M, Zhao J, Alphs L, Macek T, Panagides J: Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord 2010, 126(3):358-365.
• [18]Giorgetti M, Tecott LH: Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol 2004, 488(1-3):1-9.
• [19]Blier P, Szabo ST: Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005, 66(Suppl 8):30-40.
• [20]Franberg O, Marcus MM, Ivanov V, Schilstrom B, Shahid M, Svensson TH: Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) 2009, 204(2):251-264.
• [21]Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003, 60(11):1079-1088.
• [22]Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J: A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005, 162(7):1351-1360.
• [23]Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR: Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006, 26(6):600-609.
• [24]Abilify® (aripiprazole) Princeton, NJ: Bristol-Myers Squibb Company; 2006.
• [25]Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R: Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008, 28(1):13-20.
• [26]Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ, Miyahara S, Bauer MS, Thase ME, Wisniewski SR, Sachs GS: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006, 163(2):210-216.
• [27]Liebowitz MR, Salman E, Mech A, Dunner D, Johnson AE, Akhtar J, Pratap R: Ziprasidone monotherapy in bipolar II depression: an open trial. J Affect Disord 2009, 118(1-3):205-208.
• [28]Stahl S, Lombardo I, Loebel A, Mandel FS: Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affect Disord 2010, 122(1-2):39-45.
• [29]Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S: The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010, 11(2):81-109.
• [30]Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E: Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 2010, 13(1):5-14.
• [31]Mittmann N, Mitter S, Borden EK, Herrmann N, Naranjo CA, Shear NH: Montgomery-Asberg severity gradations. Am J Psychiatry 1997, 154(9):1320-1321.
• [32]Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997, 73(3):159-171.